S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.04 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   316.57 (-0.68%)
FB   221.44 (-0.32%)
MSFT   166.50 (-0.36%)
GOOGL   1,482.25 (+0.18%)
AMZN   1,892.00 (+1.46%)
CGC   24.15 (-2.97%)
NVDA   247.94 (-0.54%)
BABA   222.26 (-2.27%)
MU   58.97 (+2.27%)
GE   11.66 (-1.27%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.36%)
ACB   2.01 (-5.63%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.41 (-1.57%)
BAC   34.26 (-1.30%)
DIS   143.56 (-0.53%)
GILD   62.63 (-0.56%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:ATRI - Atrion Stock Price, Forecast & News

$735.00
+27.46 (+3.88 %)
(As of 01/21/2020 04:00 PM ET)
Today's Range
$714.95
Now: $735.00
$738.55
50-Day Range
$684.80
MA: $720.14
$757.60
52-Week Range
$675.34
Now: $735.00
$948.03
Volume6,799 shs
Average Volume7,061 shs
Market Capitalization$1.36 billion
P/E Ratio37.56
Dividend Yield0.88%
Beta0.15
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRI
CUSIP04990410
Phone972-390-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$152.45 million
Cash Flow$24.32 per share
Book Value$113.76 per share

Profitability

Net Income$34.26 million

Miscellaneous

Employees570
Market Cap$1.36 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive ATRI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Atrion (NASDAQ:ATRI) Frequently Asked Questions

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion announced a quarterly dividend on Tuesday, November 12th. Shareholders of record on Monday, December 2nd will be paid a dividend of $1.55 per share on Monday, December 16th. This represents a $6.20 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date is Friday, November 29th. View Atrion's Dividend History.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) announced its quarterly earnings data on Friday, November, 1st. The medical instruments supplier reported $5.15 earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $38.88 million for the quarter. Atrion had a return on equity of 16.45% and a net margin of 23.43%. View Atrion's Earnings History.

When is Atrion's next earnings date?

Atrion is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Atrion.

Has Atrion been receiving favorable news coverage?

News articles about ATRI stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atrion earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Atrion.

Are investors shorting Atrion?

Atrion saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 101,500 shares, a decline of 7.6% from the December 15th total of 109,800 shares. Based on an average trading volume of 10,500 shares, the days-to-cover ratio is currently 9.7 days. Currently, 7.1% of the company's stock are sold short. View Atrion's Current Options Chain.

Who are some of Atrion's key competitors?

What other stocks do shareholders of Atrion own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atrion investors own include ABM Industries (ABM), International Paper (IP), AT&T (T), Westrock (WRK), Exxon Mobil (XOM), Gilead Sciences (GILD), Methanex (MEOH), Pattern Energy Group (PEGI), Walgreens Boots Alliance (WBA) and AbbVie (ABBV).

Who are Atrion's key executives?

Atrion's management team includes the folowing people:
  • Mr. Emile A. Battat, Exec. Chairman (Age 81)
  • Mr. David A. Battat, Pres & CEO (Age 49)
  • Mr. Jeffery Strickland, VP, CFO, Treasurer & Sec. (Age 60)

Who are Atrion's major shareholders?

Atrion's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (1.01%), Pennsylvania Trust Co (0.56%), Hudson Valley Investment Advisors Inc. ADV (0.05%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Atrion stock include Emile A Battat, Jeffery Strickland, John P Stupp Jr and Ronald Nicholas Spaulding. View Institutional Ownership Trends for Atrion.

Which major investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Pennsylvania Trust Co. Company insiders that have sold Atrion company stock in the last year include John P Stupp Jr and Ronald Nicholas Spaulding. View Insider Buying and Selling for Atrion.

Which major investors are buying Atrion stock?

ATRI stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp and Hudson Valley Investment Advisors Inc. ADV. View Insider Buying and Selling for Atrion.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $735.00.

How big of a company is Atrion?

Atrion has a market capitalization of $1.36 billion and generates $152.45 million in revenue each year. Atrion employs 570 workers across the globe.View Additional Information About Atrion.

What is Atrion's official website?

The official website for Atrion is http://www.atrioncorp.com/.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at 972-390-9800 or via email at [email protected]


MarketBeat Community Rating for Atrion (NASDAQ ATRI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Atrion and other stocks. Vote "Outperform" if you believe ATRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel